Affiliation:
1. Department of Surgery Boston Medical Center, Boston University School of Medicine Boston MA USA
2. Division of Surgical Oncology, Department of Surgery Johns Hopkins University School of Medicine Baltimore MD USA
3. Department of Surgical Oncology Boston Medical Center 820 Harrison Avenue, FGH Building—Suite 5007 02118 Boston MA USA
Abstract
AbstractBackgroundIn early‐stage hepatocellular carcinoma (HCC), the receipt of recommended care is critical for long‐term survival. Unfortunately, not all patients decide to undergo therapy. We sought to identify factors associated with the decision to decline recommended intervention among patients with early‐stage HCC.MethodsThe National Cancer Database was queried for patients diagnosed with clinical stages I and II HCC (2004–2017). Cohorts were created based on the receipt or decline of recommended interventions–hepatectomy, liver transplantation, and ablation. Multivariable logistic regression identified predictors for declining intervention, and propensity score analysis was used to calculate the respective odds. Survival analysis was performed using the Kaplan–Meier method.ResultsOf 20,863 patients, 856 (4.1%) declined intervention. Patients who were documented as having declined intervention were more often Black (vs. other: OR, 1.3; 95% CI, 1.1–1.6; p = 0.0038), had Medicaid or no insurance (vs. Private, Medicare, or other government insurance): OR, 1.9; 95% CI, 1.6–2.3; p < 0.0001), lived in a low‐income area (vs. other: OR, 1.4; 95% CI, 1.2–1.7; p < 0.0001), and received treatment at a non‐academic center (vs. academic: OR, 2.1; 95% CI, 1.9–2.5; p < 0.0001). Patients who declined recommended interventions had worse survival compared to those who received treatment (22.9 vs. 59.2 months; p < 0.0001, respectively).ConclusionsRacial and socioeconomic disparities persist in the decision to undergo recommended treatment. Underutilization of treatment acts as a barrier to addressing racial and socioeconomic disparities in early‐stage HCC outcomes.
Funder
National Cancer Institute
T32 Boston University School of Medicine
Marc and Claire Perlman Scholarship for Pancreatic Cancer Research
Reference30 articles.
1. Globocan.Liver fact sheet. Cancer today.https://gco.iarc.fr/today/data/factsheets/cancers/11‐Liver‐fact‐sheet.pdf; Accessed March 8 2022.
2. Key statistics about liver cancer. Cancer.org.https://www.cancer.org/cancer/liver‐cancer/about/what‐is‐key‐statistics.html; Accessed March 8 2022.
3. Cancer facts & figures 2022.American cancer society.https://www.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/annual‐cancer‐facts‐and‐figures/2022/2022‐cancer‐facts‐and‐figures.pdf. Accessed: March 8 2022.
4. Global cancer statistics, 2012
5. Refusal of surgery for colon cancer: Sociodemographic disparities and survival implications among US patients with resectable disease